Published in J Gen Intern Med on February 19, 2016
Treatment of Venous Thromboembolism in Pediatric Patients. Front Pediatr (2017) 0.75
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc (2009) 5.81
Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine (Phila Pa 1976) (2003) 5.63
Prevention of venous thromboembolism. Chest (2001) 5.59
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Bias and causal associations in observational research. Lancet (2002) 5.36
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ (1998) 5.05
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med (2001) 4.33
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med (2002) 3.83
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
The crippling consequences of fractures and their impact on quality of life. Am J Med (1997) 2.98
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest (2001) 2.72
Venous thromboembolism and cancer: risks and outcomes. Circulation (2003) 2.68
Treatment of venous thromboembolism. JAMA (2014) 2.63
Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood (2005) 2.07
Antithrombotic therapy for venous thromboembolic disease. Chest (2001) 1.94
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med (2006) 1.88
Quality of reporting in systematic reviews of adverse events: systematic review. BMJ (2014) 1.81
Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med (2014) 1.75
Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med (2009) 1.53
Guidelines on the use and monitoring of heparin. Br J Haematol (2006) 1.51
A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty. J Invasive Cardiol (2001) 1.48
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost (2006) 1.35
Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc (2006) 1.20
The effects of a FRAX revision for the USA. Osteoporos Int (2009) 1.12
Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J (2006) 1.11
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost (1994) 1.08
A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood (1997) 1.06
Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med (1999) 1.03
Management of cancer treatment-induced bone loss. Nat Rev Rheumatol (2013) 0.99
Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost (2012) 0.98
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med (2007) 0.95
Heparin-induced osteoporosis and pregnancy. Curr Opin Pulm Med (2008) 0.93
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med (2009) 0.91
Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: a randomized placebo-controlled, double-blind study. Acta Orthop (2007) 0.90
Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost (2003) 0.90
Obesity and bone. Curr Osteoporos Rep (2013) 0.90
Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost (2008) 0.89
Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res (2008) 0.89
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. Bone Joint J (2013) 0.89
The safety of heparins in end-stage renal disease. Semin Dial (2006) 0.88
Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs (2001) 0.88
Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost (1990) 0.87
Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus (2009) 0.87
Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb (2003) 0.86
Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod (1999) 0.86
Oral anticoagulation for prolonging survival in patients with cancer. Cochrane Database Syst Rev (2007) 0.85
Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int (1999) 0.84
The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskelet Disord (2011) 0.83
Skin grafting followed by low-molecular-weight heparin long-term therapy in chronic venous leg ulcers. Ann Vasc Surg (2011) 0.83
Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats. Thromb Haemost (2004) 0.82
Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Jpn J Pharmacol (1997) 0.82
The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients. Curr Opin Pulm Med (2003) 0.82
Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost (2000) 0.81
Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. Nephron (1995) 0.81
Low-molecular-weight heparins in pregnancy. Pharmacotherapy (1999) 0.80
The promise of novel direct oral anticoagulants. Best Pract Res Clin Haematol (2012) 0.80
Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost (2005) 0.80
Heparins, coumarin, and bone density. Lancet (1991) 0.79
Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med (2001) 0.79
Low-molecular-weight heparins, acenocoumarol and bone density. Haemostasis (2001) 0.77
Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. Int J Clin Pract (2006) 0.77
Venous thromboembolism prophylaxis in patients undergoing abdominal or pelvic surgery for cancer--a real-world, prospective, observational French study: PRéOBS. Thromb Res (2013) 0.76
Comparison of fondaparinux with low molecular weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury. J Thromb Haemost (2013) 0.76
Low molecular weight heparins and antiplatelet drugs, and bone mineral density in dialysis patients. Adv Perit Dial (2008) 0.76